Evidence map›Paper›PMID 32665441›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function.

Anvay Ukidve, Zongmin Zhao, Alexandra Fehnel, Vinu Krishnan, Daniel C Pan, Yongsheng Gao, Abhirup Mandal, Vladimir Muzykantov, Samir Mitragotri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Biomimetic Cell Membrane-Coated MOFs System for Targeted Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anvay UkidveJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.ORCID 0000-0002-6757-7942
Zongmin ZhaoJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Alexandra FehnelJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Vinu KrishnanJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Daniel C PanJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.ORCID 0000-0003-1248-6143
Yongsheng GaoJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.ORCID 0000-0002-2347-1855
Abhirup MandalJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.ORCID 0000-0002-2543-4994
Vladimir MuzykantovDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Samir MitragotriJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138; mitragotri@seas.harvard.edu.

Funding

Vascular delivery of nanocarriers by erythrocyresR01HL143806 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2018 to 2021
$2.8M
NHLBI NIH HHS R01 HL143806
6 · The paper itself

Abstract

Erythrocytes naturally capture certain bacterial pathogens in circulation, kill them through oxidative stress, and present them to the antigen-presenting cells (APCs) in the spleen. By leveraging this innate immune function of erythrocytes, we developed erythrocyte-driven immune targeting (EDIT), which presents nanoparticles from the surface of erythrocytes to the APCs in the spleen. Antigenic nanoparticles were adsorbed on the erythrocyte surface. By engineering the number density of adsorbed nanoparticles, (i.e., the number of nanoparticles loaded per erythrocyte), they were predominantly delivered to the spleen rather than lungs, which is conventionally the target of erythrocyte-mediated delivery systems. Presentation of erythrocyte-delivered nanoparticles to the spleen led to improved antibody response against the antigen, higher central memory T cell response, and lower regulatory T cell response, compared with controls. Enhanced immune response slowed down tumor progression in a prophylaxis model. These findings suggest that EDIT is an effective strategy to enhance systemic immunity.

Indexed as

ImmunizationAnimalsAntibody FormationAntigen PresentationAntigensBiomimeticsCell Line, TumorDendritic CellsErythrocytesFemaleHumansMiceNanoparticlesSpleenVaccinationVaccinesAntigensVaccinesbiomimeticerythrocyte hitchhikingimmunizationspleen targetingvaccination

Identifiers

PMID32665441
PMCPMC7395435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.